| Name | Title | Contact Details |
|---|
Blackline Marketing specializes in helping clients in the hospitality, travel, restaurant, health care, business services, retail and food/beverage industries create integrated marketing solutions that increase revenues and maximize long-term customer engagement. Blackline Marketing helps clients in the areas of brand strategy, customer strategy, integrated marketing planning and people/process development. Clients include Northcott Hospitality/Houlihan`s restaurants, Caribou Coffee Company, HealthSource Solutions, ARC/Value Village Stores, Pebble Creek Golf Club and the MN Women`s Public Golf Association.
Morning View Care Ctr is a Centerburg, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The HCA Physician Services Group, a part of the HCA family, is focused on implementing innovative, value-added solutions that help our physicians deliver high quality, cost effective healthcare and support HCA`s commitment to the care and improvement of human life. As the physician solution for HCA, the Physician Services Group makes it easier for physicians to practice medicine by reducing the burdens of managing an independent practice and infusing the best clinical and operational standards in every office. The Physician Services Group is always looking for great people who are passionate about caring for human life. We are looking for experienced health care executives, skilled operators, area and market managers, practice managers, accountants, coders, business analysts, charge entry specialists, medical assistants and all around leaders ready for their next great opportunity.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
AposTherapy provides a clinically proven, innovative, drug-free, at-home treatment for reducing pain and improving function in patients suffering from knee osteoarthritis and chronic lower back or hip pain.